Dr. Wayne N. Leimbach, M.D.
Interventional Cardiology (Interventional Cardiology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 481
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
OK license 15626 -
Specialist
OK license 15626
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 481
- Services billed
- 958
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 518 | 460 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 379 | 368 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 91 | 88 |
| Insertion of needle into vein for collection of blood sample | 71 | 69 |
| New patient office or other outpatient visit, 45-59 minutes | 59 | 59 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 40 | 40 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 37 | 30 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 21 | 20 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 18 | 18 |
| Injection for imaging of aorta above heart valve with review by radiologist | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Tulsa, OK | 489 |
| Ezetimibe Other prescribers in Tulsa, OK | 413 |
| Atorvastatin Calcium Other prescribers in Tulsa, OK | 370 |
| Amlodipine Besylate Other prescribers in Tulsa, OK | 361 |
| Eliquis (apixaban) Other prescribers in Tulsa, OK | 308 |
| Rosuvastatin Calcium Other prescribers in Tulsa, OK | 307 |
| Spironolactone Other prescribers in Tulsa, OK | 266 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Tulsa, OK | 257 |
| Losartan Potassium Other prescribers in Tulsa, OK | 213 |
| Carvedilol Other prescribers in Tulsa, OK | 185 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $332 in total to this clinician.
| Penumbra, Inc. | $160 |
|---|---|
| Lexicon Pharmaceuticals, Inc. | $94.54 |
| Edwards Lifesciences Corporation | $39.38 |
| Abiomed | $38.48 |
| Food and Beverage | $332 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $33,960 in research payments for these studies, mostly to the institutions running them.
- Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - Dapagliflozin in Acute Decompensated Heart Failure
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.